RPV

DRUG4 trials

Conditions

HIV InfectionsInfection, Human Immunodeficiency Virus

Phase 1

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2016-05-11End: 2016-10-24Updated: 2019-07-15

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

RecruitingNCT05418868

ViiV HealthcareHIV Infections

Start: 2022-06-14End: 2027-06-08Target: 214Updated: 2025-12-18

Phase 2

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

CompletedNCT02120352

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2014-04-28End: 2023-04-20Updated: 2024-06-12

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

CompletedNCT03639311

ViiV HealthcareHIV Infections

Start: 2018-09-24End: 2023-01-30Updated: 2024-06-11

2025-07-041 citations

Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.

2023-07-1410 citations

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

AIDS2021-10-1334 citations

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

Open Forum Infectious Diseases2021-08-2555 citations

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).

2021-05-3156 citations

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

JAIDS Journal of Acquired Immune Deficiency Syndromes2020-08-21135 citations

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

UNC Libraries2020-08-19

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir

Journal of Antimicrobial Chemotherapy2020-03-2711 citations

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults

Journal of Antimicrobial Chemotherapy2019-11-2230 citations

2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results

Open Forum Infectious Diseases2019-10-018 citations

Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

HIV Research & Clinical Practice2019-09-0335 citations

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.

2018-08-278 citations

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

Antimicrobial Agents and Chemotherapy2017-07-2547 citations

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

2017-07-24375 citations

RPV

Sponsors

Conditions

Phase 1

Phase 2

Related Papers